Search
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalBelimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immun...
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411]
Bifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
Etozoline
go.drugbank.com/drugs/DB08982ExperimentalEtozoline is marketed in Europe under the names Diulozin, Elkapin, and Etopinil. Etozoline is a loop diuretic.
Estriol
go.drugbank.com/drugs/DB04573ApprovedInvestigationalVet approvedIt has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.
Diethylamino hydroxybenzoyl hexyl benzoate
go.drugbank.com/drugs/DB11269ApprovedDiethylamino hydroxybenzoyl hexyl benzoate was approved in Europe in 2005, and is also marketed in the U.S., South America, Mexico, Japan and Taiwan.
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnNicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawn[A251805] Metamizole is still used in certain countries in Europe, Asia and South America.[A251805]
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalIn Europe, Hexaminolevulinate is marketed under the brand Hexvix®.
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.